Get the Stockscreener App
22.25
0.95%
0.135
Gh Research Plc stock is traded at $22.25, with a volume of 18,869.
It is up +0.95% in the last 24 hours and up +10.27% over the past month.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
See More
Previous Close:
$22.12
Open:
$22.37
24h Volume:
18,869
Relative Volume:
0.08
Market Cap:
$1.52B
Revenue:
-
Net Income/Loss:
$-48.26M
P/E Ratio:
-28.17
EPS:
-0.7899
Net Cash Flow:
$-45.04M
1W Performance:
+1.78%
1M Performance:
+10.27%
6M Performance:
+51.39%
1Y Performance:
+99.91%
1-Day Range:
$21.90
$23.03
1-Week Range:
$21.54
$23.84
52-Week Range:
$10.96
$24.66
Gh Research Plc Stock (GHRS) Company Profile
Compare GHRS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GHRS
Gh Research Plc
|
22.21 | 1.52B | 0 | -48.26M | -45.04M | -0.7899 |
VRTX
Vertex Pharmaceuticals Inc
|
435.62 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
640.47 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
800.86 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.89 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.09 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Gh Research Plc Stock (GHRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-13-25 | Initiated | Needham | Buy |
| Jun-04-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-13-25 | Initiated | Guggenheim | Buy |
| Mar-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Feb-13-25 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-16-22 | Initiated | H.C. Wainwright | Buy |
| Jun-16-22 | Initiated | ROTH Capital | Buy |
View All
Gh Research Plc Stock (GHRS) Latest News
(GHRS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Assessing GH Research (GHRS) Valuation After Positive Phase 2b Data For GH001 In Treatment Resistant Depression - Sahm
GH Research to Present New GH001 Phase 2b Data in Treatment-Resistant Depression at ASCP 2026 - TipRanks
GH Research (NASDAQ: GHRS) highlights Phase 2b GH001 gains in treatment-resistant depression - Stock Titan
GHRS Technical Analysis | Trend, Signals & Chart Patterns | GH RESEARCH PLC (NASDAQ:GHRS) - ChartMill
[EFFECT] GH Research PLC SEC Filing - Stock Titan
GH Research: Rapid Onset And Short Action Change The Treatment Paradigm (NASDAQ:GHRS) - Seeking Alpha
GHRS Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
H.C. Wainwright lowers GH Research stock price target on dilution By Investing.com - Investing.com South Africa
H.C. Wainwright lowers GH Research stock price target on dilution - Investing.com
Lynx1 and Weston Nichols report 17.4% stake in GH Research (NASDAQ: GHRS) - Stock Titan
Phase 2b JAMA Data and New Financing Tools Could Be A Game Changer For GH Research (GHRS) - simplywall.st
Assessing GH Research (GHRS) Valuation After Key Phase 2b Results And Phase 3 Trial Plans - Yahoo Finance
GHRS SEC FilingsGh Research Plc 10-K, 10-Q, 8-K Forms - Stock Titan
GHRS Maintained by Cantor Fitzgerald -- Price Target Raised to $35 - GuruFocus
Lynx1 discloses 15.2% stake in GHRS (GHRS) via Schedule 13G/A - Stock Titan
GHRS Maintained by CitizensPrice Target Lowered to $39.00 - GuruFocus
Cantor Fitzgerald raises GH Research stock price target on adoption outlook - Investing.com UK
These Analysts Revise Their Forecasts On GH Research After Q1 Results - Benzinga
Canaccord reiterates GH Research stock rating on phase 3 progress By Investing.com - Investing.com Nigeria
Cantor Fitzgerald raises GH Research stock price target on adoption outlook By Investing.com - Investing.com South Africa
Canaccord reiterates GH Research stock rating on phase 3 progress - Investing.com
Citizens cuts GH Research stock price target on equity financing - Investing.com
Citizens cuts GH Research stock price target on equity financing By Investing.com - Investing.com Australia
GH Research PLC announces $200 million at-the-market equity offering - Investing.com Nigeria
GH Research Launches $200 Million At-the-Market Share Offering With Stifel - TipRanks
GH Research PLC announces $200 million at-the-market equity offering By Investing.com - Investing.com South Africa
[6-K] GH Research PLC Current Report (Foreign Issuer) | GHRS SEC FilingForm 6-K - Stock Titan
GH Research Releases Q1 2026 Financial Results - AlphaStreet
GH Research PLCMay offer up to $400 million in securitiesSEC filing - marketscreener.com
Gh Research plcenters at-the-market equity offering sales agreement with StifelSEC filing - marketscreener.com
GH Research (NASDAQ: GHRS) files F-3 to register $400M in securities - Stock Titan
GH Research (NASDAQ: GHRS) launches $200M at‑the‑market share program - Stock Titan
GH Research Posts Wider Q1 2026 Loss as R&D and Admin Costs Rise - TipRanks
Earnings Flash (GHRS) GH Research Posts Q1 Loss $0.31 a Share, vs. FactSet Est of $0.29 Loss - marketscreener.com
GH Research Reports First Quarter 2026 Financial Results and Provides Business Update - The Manila Times
GH Research (Nasdaq: GHRS) widens Q1 loss but keeps $267M cash buffer - Stock Titan
GH Research PLC Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
TradingKey - TradingKey
Experimental depression drug GH001 prepares for Phase 3 after JAMA study - Stock Titan
GH Research PLC schedules annual general meeting for June 25 in Dublin By Investing.com - Investing.com India
GH Research PLC schedules annual general meeting for June 25 in Dublin - Investing.com UK
Gh Research Plc Stock (GHRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.25%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):